schließen (X)

News

15.01.2019
The PicoStar Laser for Removal of Tattoos, Pigmented Lesions and Permanent Makeup

Tattoos have increased tremendously in popularity – a phenomenon that can be seen across the world. In France alone, the number of tattooists has increased ten-fold within a decade. Twenty per cent of people between the ages of 25 and 34 have one. And in Germany according to estimates, approximately 10% of the population has […]

Read more >

08.10.2018
Food activates brown fat

Brown fat consumes energy, which is the reason why it could be important for preventing obesity and diabetes. Working together with an international team, researchers at the Technical University of Munich (TUM) were able to demonstrate that food also increases the thermogenesis of brown fat, and not just cold as previously assumed.     Brown […]

Read more >

31.05.2018
Cutera Announces Opening of New Office and Training Center in Madrid

CUTERA, INC., (Nasdaq:CUTR) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announces the opening of its new office and training center located in Madrid, Spain. The new office will enable Cutera to better serve customers throughout the European market with direct sales, marketing and service […]

Read more >

20.03.2018
Weekly Fish Consumption Linked to Better Sleep, Higher IQ

Children who eat fish at least once a week sleep better and have IQ scores that are 4 points higher, on average, than those who consume fish less frequently or not at all, according to new findings from the University of Pennsylvania published today in Scientific Reports, a Nature journal.     Previous studies showed a relationship between omega-3s, the fatty […]

Read more >

Science News


Transconjunctival lower lid blepharoplasty by radiofrequency surgery

Eyelid corrections are one of the most common aesthetic operations performed today. The majority of this is due to sliplid treatment with an upper eyelid blepharoplasty. The lower eyelid blepharoplasty with the removal of “tear sacs” is technically more demanding and is performed less frequently. The removal of fat from the lower eyelid can be […]

Read more >

, ,
Therapy of patients with mild, moderate and severe onychomycosis by the munich model (ND:YAG laser and co-treatment with topical antimycotic therapy): adjuvant short.time and low-dose treatment with itraconazole can optimize the result

In the western world, about 10% of the population is affected by fungal nail changes and there is a massive accumulation in older people, especially after the age of 60, slow nail growth, orthopaedic problems and after injuries to the nail organ, as well as in athletes or miners. Other risk factors are a weakened […]

Read more >


International expert consensus on the use of AboBotulinum Toxin A (AboTA) for facial rejuvenation and primary hyperhidrosis

Redaelli A, Saromytskaya A, Rowland Payne C et al (2017) International expert consensus on the use of AboBotulinum Toxin A (AboTA) for facial rejuvenation and primary hyperhidrosis. CosMed 3(2): 70 – 80.   Redaelli A.a, Saromytskaya A b, Rowland Payne C.c., Manturova N. d, Battistella M.e, Saban Y.f, Panova O.g, Wollina U.h, Landau M. i, Atamanov […]

Read more >

Industry news

15.01.2019
The PicoStar Laser for Removal of Tattoos, Pigmented Lesions and Permanent Makeup

Tattoos have increased tremendously in popularity – a phenomenon that can be seen across the world. In France alone, the number of tattooists has increased ten-fold within a decade. Twenty per cent of people between the ages of 25 and 34 have one. And in Germany according to estimates, approximately 10% of the population has […]

Read more >

12.10.2017
New patient group „men“ – hyaluronic acid as an important tool

In our dermatology practice we use increasingly cross-linked fillers in men, such as Z FILL Deep2 for regenerative augmentation. On behalf of a 47 year old man, the approach and the pleasing results after three months are exemplified.   A 47 year old man without preceeding diseases introduced himself in our practice for aesthetic treatment […]

Read more >

15.06.2017
Syneron Candela’s PicoWay picosecond laser now with three wavelengths and resolve fractional

PicoWay® picosecond laser received U.S. Food and Drug Administration (FDA) clearance for a new ultra-short 785 nm wavelength, making it the third FDA cleared wavelength for PicoWay. The new ultra-short 785nm wavelength is the first of its kind in the aesthetic market, utilizing a titanium sapphire laser for the removal of blue and green inks. […]

Read more >

16.05.2017
CUTERA Launches truSculpt® 3D … A New Dimension in Body Sculpting

BRISBANE, Calif., May 16, 2017 (GLOBE NEWSWIRE) — CUTERA (Nasdaq:CUTR), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced the launch of truSculpt® 3D, the newest advancement in non-surgical body sculpting, offering up to 24 percent fat reduction in a single treatment.   truSculpt 3D utilizes a controlled, monopolar radio frequency (RF) technology at 2 MHz to deliver […]

Read more >

Further topics

11.03.2016 Companies
VICHY Announces the First Annual VICHY EXPOSOME GRANT

VICHY Laboratoires, the VICHY EXPOSOME GRANT will promote and encourage research activity on the skin exposome. One research grant of 15 000 € will be awarded annually to a research project proposal in the field of exposome and skin.   What is exposome? The human body is subjected to and responds to complex exposures throughout […]

Read more >

21.07.2015 Companies
Juvéderm® VOLIFT™ Retouch extends the VYCROSS™ Collection

Allergan Symposium at the 13. AMWC in Monaco: The day long symposium under the guidance of Dr. Koenraad de Boulle from Belgium was dedicated to the motto „Achieving real expressions in challenging patients“. Customized approaches to facial rejuvenation to achieve a natural look, were presented.   Mauricio de Maio from Brazil presented several difficult cases […]

Read more >

14.03.2016 Industry news
Merck Initiates Phase III Study of MSB11022

Merck, a leading science and technology company, today announced the initiation of a global Phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This milestone is a strong reflection of Merck’s progress in biosimilars, with the goal of delivering high-quality biologics to patients all over the world. “With the […]

Read more >

Login

Lost your password?